Katie L Lutz1, Lenore Holte, Stephanie A Kliethermes, Carrie Stephan, Katherine D Mathews. 1. From the University of Iowa Carver College of Medicine (K.L.L.), Department of Pediatrics (L.H., C.S., K.D.M.), Department of Communication Sciences and Disorders (L.H.), College of Public Health (S.A.K.), and Department of Neurology (K.D.M.), University of Iowa, Iowa City.
Abstract
OBJECTIVE: To describe the hearing loss in facioscapulohumeral muscular dystrophy (FSHD) and examine the relationship to genotype. METHODS: Medical records of all individuals with FSHD seen at the University of Iowa neuromuscular clinic between July 2006 and July 2012 (n = 59) were reviewed. Eleven had significant hearing loss and no non-FSHD cause. All available audiology records for these individuals were analyzed. The relationship between the FSHD mutation (EcoRI/BlnI fragment size) and hearing loss was evaluated using a logistic regression analysis. RESULTS: In patients with hearing loss, recalled age at onset of facial weakness ranged from birth to 5 years and shoulder weakness was 3 to 15 years. The age at diagnosis of hearing loss ranged from birth to 7 years. Only 2 were identified by newborn hearing screen. Most audiograms demonstrated a bilateral, sloping, high-frequency sensorineural hearing loss. Of the 4 patients with more than 5 years of data, 3 had progression of hearing loss. Logistic regression showed statistically significant negative association between the presence of hearing loss and EcoRI/BlnI fragment size (p = 0.0207). CONCLUSIONS: FSHD with a small EcoRI/BlnI fragment is associated with a bilateral, progressive, sloping, high-frequency hearing loss with onset in childhood. Patients with FSHD and small EcoRI/BlnI fragment sizes should have hearing screened, even if the child passed newborn hearing screening.
OBJECTIVE: To describe the hearing loss in facioscapulohumeral muscular dystrophy (FSHD) and examine the relationship to genotype. METHODS: Medical records of all individuals with FSHD seen at the University of Iowa neuromuscular clinic between July 2006 and July 2012 (n = 59) were reviewed. Eleven had significant hearing loss and no non-FSHD cause. All available audiology records for these individuals were analyzed. The relationship between the FSHD mutation (EcoRI/BlnI fragment size) and hearing loss was evaluated using a logistic regression analysis. RESULTS: In patients with hearing loss, recalled age at onset of facial weakness ranged from birth to 5 years and shoulder weakness was 3 to 15 years. The age at diagnosis of hearing loss ranged from birth to 7 years. Only 2 were identified by newborn hearing screen. Most audiograms demonstrated a bilateral, sloping, high-frequency sensorineural hearing loss. Of the 4 patients with more than 5 years of data, 3 had progression of hearing loss. Logistic regression showed statistically significant negative association between the presence of hearing loss and EcoRI/BlnI fragment size (p = 0.0207). CONCLUSIONS:FSHD with a small EcoRI/BlnI fragment is associated with a bilateral, progressive, sloping, high-frequency hearing loss with onset in childhood. Patients with FSHD and small EcoRI/BlnI fragment sizes should have hearing screened, even if the child passed newborn hearing screening.
Authors: Christopher R S Banerji; Maryna Panamarova; Johanna Pruller; Nicolas Figeac; Husam Hebaishi; Efthymios Fidanis; Alka Saxena; Julian Contet; Sabrina Sacconi; Simone Severini; Peter S Zammit Journal: Hum Mol Genet Date: 2019-04-15 Impact factor: 6.150
Authors: Abhijit Dandapat; Darko Bosnakovski; Lynn M Hartweck; Robert W Arpke; Kristen A Baltgalvis; Derek Vang; June Baik; Radbod Darabi; Rita C R Perlingeiro; F Kent Hamra; Kalpna Gupta; Dawn A Lowe; Michael Kyba Journal: Cell Rep Date: 2014-08-28 Impact factor: 9.423
Authors: Jeffrey M Statland; Colleen M Donlin-Smith; Stephen J Tapscott; Richard J L F Lemmers; Silvère M van der Maarel; Rabi Tawil Journal: Neurology Date: 2015-11-11 Impact factor: 9.910
Authors: Amy E Campbell; Andrea E Belleville; Rebecca Resnick; Sean C Shadle; Stephen J Tapscott Journal: Hum Mol Genet Date: 2018-08-01 Impact factor: 6.150
Authors: Rianne J M Goselink; Tim H A Schreuder; Karlien Mul; Nicol C Voermans; Maaike Pelsma; Imelda J M de Groot; Nens van Alfen; Bas Franck; Thomas Theelen; Richard J Lemmers; Jean K Mah; Silvère M van der Maarel; Baziel G van Engelen; Corrie E Erasmus Journal: BMC Neurol Date: 2016-08-17 Impact factor: 2.474
Authors: Abhijit Dandapat; Benjamin J Perrin; Christine Cabelka; Maria Razzoli; James M Ervasti; Alessandro Bartolomucci; Dawn A Lowe; Michael Kyba Journal: PLoS One Date: 2016-03-15 Impact factor: 3.240